<DOC>
	<DOCNO>NCT01598324</DOCNO>
	<brief_summary>This ancillary study clinical trial conduct Massachusetts General Hospital . Investigators MGH conduct clinical trial test efficacy ziprasidone together escitalopram treatment-resistant depression ( NCT00633399 ) . This observational study involve magnetic resonance scan examine brain chemistry ( neurotransmitter level ) , brain activity , functional connection brain region participate trial . The neurotransmitter interest glutamate , glutamine , GABA . Comparisons make individual receive ziprasidone individual receive inactive placebo . Differences participant respond standard antidepressant require additional medication also examine . All participant baseline magnetic resonance scan start medication . The second scan 8 week escitalopram treatment respond follow 8 week escitalopram plus ziaprasidone placebo ( 16 week start ) respond escitalopram alone . Participants complete standard rating scale depression visit .</brief_summary>
	<brief_title>Functional Neurochemical Correlates Treatment Response Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Depressive Disorder , Treatment-Resistant</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<mesh_term>Serotonin Uptake Inhibitors</mesh_term>
	<criteria>Aged 1865 Meets DSMIV criterion major depressive disorder Meets eligibility criterion clinical trial ziprasidone augmentation escitalopram Capable providing inform consent Meets exclusion criterion augmentation clinical trial protocol Pregnancy unwillingness avoid pregnancy trial Current past psychosis bipolar disorder Substance abuse dependence past six month Clinically significant suicidality Unstable cardiovascular , hepatic , renal , respiratory , endocrine , neurological , hematological disease uncontrolled seizure Use concomitant medication act glutamate GABA neurotransmission Contraindication magnetic resonance imaging ( metal implant device , occupational metal exposure , significant claustrophobia )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>magnetic resonance imaging</keyword>
	<keyword>magnetic resonance spectroscopy</keyword>
	<keyword>depression</keyword>
	<keyword>escitalopram</keyword>
	<keyword>selective serotonin reuptake inhibitor</keyword>
	<keyword>treatment-resistant depression</keyword>
	<keyword>ziprasidone</keyword>
</DOC>